Novavax Inc (NVAX)
3.94
+0.05
(+1.29%)
USD |
NASDAQ |
Apr 18, 12:08
Novavax Enterprise Value: 143.93M for April 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 17, 2024 | 143.93M |
| April 16, 2024 | 157.92M |
| April 15, 2024 | 176.12M |
| April 12, 2024 | 198.51M |
| April 11, 2024 | 201.31M |
| April 10, 2024 | 195.71M |
| April 09, 2024 | 218.10M |
| April 08, 2024 | 219.50M |
| April 05, 2024 | 218.10M |
| April 04, 2024 | 220.90M |
| April 03, 2024 | 234.90M |
| April 02, 2024 | 233.50M |
| April 01, 2024 | 250.29M |
| March 28, 2024 | 268.49M |
| March 27, 2024 | 278.28M |
| March 26, 2024 | 258.69M |
| March 25, 2024 | 272.69M |
| March 22, 2024 | 257.29M |
| March 21, 2024 | 260.09M |
| March 20, 2024 | 275.48M |
| March 19, 2024 | 290.88M |
| March 18, 2024 | 318.87M |
| March 15, 2024 | 339.86M |
| March 14, 2024 | 296.48M |
| March 13, 2024 | 334.26M |
| Date | Value |
|---|---|
| March 12, 2024 | 307.67M |
| March 11, 2024 | 317.47M |
| March 08, 2024 | 362.26M |
| March 07, 2024 | 384.65M |
| March 06, 2024 | 384.65M |
| March 05, 2024 | 379.05M |
| March 04, 2024 | 367.85M |
| March 01, 2024 | 353.86M |
| February 29, 2024 | 290.88M |
| February 28, 2024 | 216.70M |
| February 27, 2024 | 442.03M |
| February 26, 2024 | 369.25M |
| February 23, 2024 | 339.86M |
| February 22, 2024 | 280.30M |
| February 21, 2024 | 154.74M |
| February 20, 2024 | 175.67M |
| February 16, 2024 | 179.86M |
| February 15, 2024 | 199.39M |
| February 14, 2024 | 171.48M |
| February 13, 2024 | 143.58M |
| February 12, 2024 | 178.46M |
| February 09, 2024 | 161.72M |
| February 08, 2024 | 128.24M |
| February 07, 2024 | 126.84M |
| February 06, 2024 | 147.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-349.18M
Minimum
Mar 23 2023
22.60B
Maximum
Feb 08 2021
4.103B
Average
848.87M
Median
Enterprise Value Benchmarks
| Pfizer Inc | 201.97B |
| Moderna Inc | 31.00B |
| Agilent Technologies Inc | 40.24B |
| Align Technology Inc | 21.57B |
| Lexicon Pharmaceuticals Inc | 328.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.39M |
| Revenue (Quarterly) | 253.40M |
| Total Expenses (Quarterly) | 436.97M |
| EPS Diluted (Quarterly) | -1.47 |
| Gross Profit Margin (Quarterly) | 38.84% |
| Profit Margin (Quarterly) | -70.40% |
| Earnings Yield | -141.1% |
| Normalized Earnings Yield | -141.12 |